Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study With a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Once Daily in Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and Sulfonylurea

NCT01392677 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01392677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01392677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study With a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Once Daily in Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and Sulfonylurea
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2011
Completion date
August 31, 2013
Enrollment
311 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

high hba1c level, inadequate glycaemic control, type 2 diabetes mellitus